Influence of lornoxicam on serum pepsinogen levels.
Serum pepsinogen I was determined radioimmunologically in 18 patients suffering from lumbar backache syndromes. These patients were then treated with lornoxicam 4 mg twice daily over a period of 2 weeks. No significant increase in the serum pepsinogen I level was found in 17 (94.4%) of cases. Using the serum pepsinogen I as a parameter for the integrity of the gastric mucosa, this suggests good gastric tolerance of lornoxicam.
Kullich
W
W
Rehabilitation Centre for Rheumatic and Cardiovascular Diseases, Saalfelden, Austria.
Klein
G
G
Pöllmann
G
G
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001416:Back Pain / Q000097:blood / Q000188:drug therapy; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood*; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010435:Pepsinogens; D010894:Piroxicam; C059451:lornoxicam